Sentiment for Volitionrx LTD (NYSEMKT:VNRX)
Volitionrx LTD (NYSEMKT:VNRX) institutional sentiment decreased to 1.25 in 2018 Q2. Its down -2.00, from 3.25 in 2018Q1. The ratio dived, as 10 active investment managers opened new and increased holdings, while 8 decreased and sold their equity positions in Volitionrx LTD. The active investment managers in our partner’s database now have: 4.42 million shares, down from 9.29 million shares in 2018Q1. Also, the number of active investment managers holding Volitionrx LTD in their top 10 holdings decreased from 1 to 0 for a decrease of 1. Sold All: 4 Reduced: 4 Increased: 5 New Position: 5.
VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers. The company has market cap of $75.97 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It currently has negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.
The stock decreased 6.52% or $0.15 during the last trading session, reaching $2.15. About 122,022 shares traded or 16.59% up from the average. VolitionRx Limited (NYSEMKT:VNRX) has declined 18.02% since November 14, 2017 and is downtrending. It has underperformed by 33.64% the S&P500.
Lagoda Investment Management L.P. holds 2.59% of its portfolio in VolitionRx Limited for 3.12 million shares. Knoll Capital Management Lp owns 351,538 shares or 0.6% of their US portfolio. Moreover, Garrison Bradford & Associates Inc has 0.03% invested in the company for 15,500 shares. The Wisconsin-based Skylands Capital Llc has invested 0.01% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 5 shares.
Since January 1, 0001, it had 3 insider buys, and 0 sales for $121,957 activity.